iCellate Medical AB

is a company dedicated to cancer profiling for precision oncology and early cancer detection. Established in 2011, iCellate specializes in developing and providing cancer profiling services through its innovative platforms, CellMate® and GeneMate®. CellMate® is a next generation circulating tumor cell (CTC)-based platform for cancer cell detection and comprehensive biomarker analysis. GeneMate® offers analysis for hereditary cancer and gBRCA testing. Despite the lack of specific information on industries and headquarters, iCellate's focus on utilizing advanced technologies for cancer diagnostics makes it an intriguing prospect for potential investors. As of now, there is no information available about the last investment and the investors involved. The potential of iCellate's innovative solutions in the burgeoning field of precision oncology could make it an attractive opportunity for venture capital firms seeking to invest in the healthcare and biotechnology sectors.